Lord, Abbett & Co’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Lord, Abbett & Co’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-439,098	Closed	-$47.1M	–	601
2023 Q1	$47.1M	Buy	439,098 +136,040	+45%	+$15.7M	0.17%	193
2022 Q4	$33.3M	Buy	+303,058	New	+$19.7M	0.12%	249

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Lord, Abbett & Co's RXDX Position: Q2 2023 in Review

Lord, Abbett & Co sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 439,098 shares — an estimated $47.1M sold.

Lord, Abbett & Co first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $47.1M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Lord, Abbett & Co reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Lord, Abbett & Co sold 439,098 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $47.1M.
Lord, Abbett & Co first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Lord, Abbett & Co's Prometheus Biosciences, Inc. Common Stock position peaked at $47.1M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Lord, Abbett & Co's 13F filing for Q2 2023, filed 14 Aug 2023.